Cyclacel Pharmaceuticals Announces Reverse Stock Split

BERKELEY HEIGHTS, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it will implement a 1-for-15 Reverse Stock Split of its common stock (“Reverse Stock Split”), effective at 5:00 p.m. Eastern Time on Friday, December 15, 2023. The Reverse Stock Split, which was approved by stockholders at the Company’s Special Meeting of Stockholders on December 8, 2023, is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on The Nasdaq Capital Market. Beginning with the opening of trading on Monday, December 18, 2023, the Company’s common stock will trade on The Nasdaq Capital Market on a split-adjusted basis under the existing symbol “CYCC” and a new CUSIP number 23254L801.

Read more at globenewswire.com